Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy
Adoptive cell transfer (ACT) using T cell receptor (TCR) gene-modified T cells is an exciting and rapidly evolving field. Numerous preclinical and clinical studies have demonstrated various levels of feasibility, safety, and efficacy using TCR-engineered T cells to treat cancer and viral infections. Although evidence suggests their use can be effective, to what extent and how to improve these therapeutics are still matters of investigation. As TCR affinity has been generally accepted as the central role in defining T cell specificity and sensitivity, selection for and generation of high affinity TCRs has remained a fundamental approach to design more potent T cells. However, traditional methods for affinity-enhancement by random mutagenesis can induce undesirable cross-reactivity causing on- and off-target adverse events, generate exhausted effectors by overstimulation, and ignore other kinetic and cellular parameters that have been shown to impact antigen specificity. In this Focussed Research Review, we comment on the preclinical and clinical potential of TCR gene-modified T cells, summarize our contributions challenging the role TCR affinity plays in antigen recognition, and explore how structure-guided design can be used to manipulate antigen specificity and TCR cross-reactivity to improve the safety and efficacy of TCR gene-modified T cells used in ACT.
KeywordsT cell T cell receptor (TCR) TCR affinity TCR cross-reactivity Adoptive cell transfer PIVAC 18
Adoptive cell transfer
Altered peptide ligand
Hepatitis C virus
Peripheral blood lymphocyte
Peptide-major histocompatibility complex
T cell receptor
TT Spear, BD Evavold, BMB, and MIN designed the research, performed experiments, and analyzed the data summarized in the Focussed Research Review as well as wrote and critically revised the manuscript.
The authors’ original work described and summarized in this Focussed Research Review was funded by the National Cancer Institute (Grants F30 CA180731 to Spear; P01 CA154779 to Nishimura) and the National Institute of Allergy and Infectious Disease (Grants R01 AI129543 to Baker & Nishimura; R01 AI096879 to Evavold).
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Spear TT (2016) The Impact of altered T cell receptor—peptide-major histocompatibility complex interactions on antigen recognition and T cell function. Doctoral Disseration, Loyola University ChicagoGoogle Scholar
- 15.Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, Rosenberg SA, Nishimura MI (1995) Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Can Res 55:748–752Google Scholar
- 19.Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, Moore T, Brasic N, McKee MD, Nishimura MI (2006) Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology 43:973–981. https://doi.org/10.1002/hep.21157 CrossRefPubMedGoogle Scholar
- 20.Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA (2006) Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177:6548–6559CrossRefGoogle Scholar
- 26.Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA (2009) Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 15:169–180. https://doi.org/10.1158/1078-0432.ccr-08-1638 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Spear TT, Wang Y, Smith TW Jr, Simms PE, Garrett-Mayer E, Hellman LM, Baker BM, Nishimura MI (2018) Altered peptide ligands impact the diversity of polyfunctional phenotypes in T cell receptor gene-modified T cells. Mol Ther 26:996–1007. https://doi.org/10.1016/j.ymthe.2018.01.015 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, Mackensen A, Kast WM, Le Poole IC, Nishimura MI (2009) Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother 58:719–728. https://doi.org/10.1007/s00262-008-0594-2 CrossRefPubMedGoogle Scholar
- 42.Foley KC, Spear TT, Murray DC, Nagato K, Garrett-Mayer E, Nishimura MI (2017) HCV T cell receptor chain modifications to enhance expression, pairing, and antigen recognition in T cells for adoptive transfer. Mol Ther Oncolytics 17:105–115. https://doi.org/10.1016/j.omto.2017.05.004 CrossRefGoogle Scholar
- 47.Zhang Y, Liu Y, Moxley KM, Golden-Mason L, Hughes MG, Liu T, Heemskerk MH, Rosen HR, Nishimura MI (2010) Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog 6:e1001018. https://doi.org/10.1371/journal.ppat.1001018 CrossRefPubMedPubMedCentralGoogle Scholar
- 56.Pryshchep S, Zarnitsyna VI, Hong J, Evavold BD, Zhu C (2014) Accumulation of serial forces on TCR and CD8 frequently applied by agonist antigenic peptides embedded in MHC molecules triggers calcium in T cells. J Immunol 193:68–76. https://doi.org/10.4049/jimmunol.1303436 CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Chodon T, Comin-Anduix B, Chmielowski B et al (2014) Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 20:2457–2465. https://doi.org/10.1158/1078-0432.ccr-13-3017 CrossRefPubMedPubMedCentralGoogle Scholar
- 65.Harris DT, Wang N, Riley TP, Anderson SD, Singh NK, Procko E, Baker BM, Kranz DM (2016) Deep mutational scans as a guide to engineering high affinity T cell receptor interactions with peptide-bound major histocompatibility complex. J Biol Chem 291:24566–24578. https://doi.org/10.1074/jbc.M116.748681 CrossRefPubMedPubMedCentralGoogle Scholar
- 66.Border EC, Sanderson JP, Weissensteiner T, Gerry AB, Pumphrey NJ (2019) Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate. Oncoimmunology 8:e1532759. https://doi.org/10.1080/2162402x.2018.1532759 CrossRefPubMedGoogle Scholar
- 67.Gee MH, Sibener LV, Birnbaum ME, Jude KM, Yang X, Fernandes RA, Mendoza JL, Glassman CR, Garcia KC (2018) Stress-testing the relationship between T cell receptor/peptide-MHC affinity and cross-reactivity using peptide velcro. Proc Natl Acad Sci USA 115:E7369–E7378. https://doi.org/10.1073/pnas.1802746115 CrossRefPubMedGoogle Scholar